Clinical Trials

NanOlogy enrolls first patient in phase 1/2 clinical trial of NanoDoce to treat bladder cancer

NanOlogy, a clinical-stage oncology company, announced the first patient has been enrolled in a clinical trial of NanoDoce (sterile submicron particle docetaxel suspension) for treatment of bladder cancer.

Puma Biotechnology expands cohorts in phase II SUMMIT trial of Neratinib

Puma Biotechnology, a biopharmaceutical company, has expanded two additional cohorts from the Phase II SUMMIT clinical trial investigating its lead drug candidate neratinib in patients with solid tumors who have an activating EGFR or HER2 mutation.

ViiV Healthcare announces Juluca (dolutegravir/rilpivirine) maintains HIV viral suppression at 148-weeks

ViiV Healthcare today presented three year results from the SWORD 1 & 2 studies, demonstrating that 84% (432/513) of participants who switched from their current three- or four-drug antiretroviral regimen to a 2-drug regimen of dolutegravir (ViiV Healthcare) and rilpivirine (Janssen Sciences Ireland UC, part of the Janssen Pharmaceutical Companies of Johnson & Johnson) maintained viral suppression (viral load ≤50 copies/mL).

QUE Oncology launches phase 2 trials in the US

Clinical stage biotechnology company QUE Oncology today announces the launch of its Phase II trials which will see its novel non-hormonal therapy, for women with breast cancer suffering hot flashes and night sweats, tested at key sites in the United States.

Sangamo, Pfizer announce phase 1/2 interim data for investigational hemophilia A gene therapy

Sangamo Therapeutics and Pfizer announced interim data from the Phase 1/2 Alta study evaluating investigational SB-525 gene therapy for severe hemophilia A.

Cellectis secures FDA nod for phase 1 trial of UCARTCS1 in MM

Cellectis has secured approval from the US Food and Drug Administration (FDA) to launch a phase 1 clinical trial for the evaluation of its gene-edited T-cell product candidate UCARTCS1 as a potential treatment for multiple myeloma (MM).

Roche’s ipatasertib combo yields promising results in Phase Ib breast cancer trial

Roche said that ipatasertib, in combination with Tecentriq (atezolizumab) and chemotherapy, demonstrated promising anti-tumor activity in advanced triple-negative breast cancer in a Phase Ib study.

Silence seeks UK MHRA approval to launch first-in-human study of SLN124

Silence Therapeutics has filed a clinical trial application (CTA) with the UK Medicines and Healthcare products Regulatory Agency (MHRA), seeking approval to launch a phase Ib trial for the investigational drug, SLN124.

Evgen’s SFX-01 meets goals in phase 2 metastatic breast cancer trial

UK-based clinical-stage company Evgen Pharma reported that its phase 2 STEM trial evaluating SFX-01 for the treatment of metastatic breast cancer has met its primary endpoints.